AGP Executive Report
Last update: 9 hours agoPayer Pressure in Eye Care: ASRS research links step therapy for Vabysmo (faricimab) in diabetic macular edema to treatment delays and added burdens for patients and clinics, while another ASRS abstract finds retina-only practices dismiss patients who are often younger, male, and from lower-income areas. Medication Safety at Home: Doctors warn that some medicines can lose strength or become unsafe soon after opening, and “throw it out after a month” isn’t universal—check storage, appearance, and the label. Pediatric Antibiotic Expansion: The FDA accepted Shionogi’s sNDA to expand cefiderocol use to pediatric patients with serious Gram-negative infections, including HABP/VABP and cUTIs, with a PDUFA target of Feb. 23, 2027. Global Pharma Deals: Pakistan and China wrapped a B2B conference with about $850M in agreements, including contracts and MoUs aimed at local vaccine and drug manufacturing. Public Health Alerts: Thailand launched public consultation on a revised surrogacy bill, while Nigeria faces calls to expand health insurance coverage beyond the small share currently insured. Clinical Innovation: A personalized TMS trial for PTSD reported reduced amygdala threat reactivity after scan-guided stimulation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
